The Pharmaletter

QurAlis

A clinical-stage biotechnology company based in Cambridge, Massachusetts. The company operates as a U.S.-centered research and development organization focused on neurodegenerative disease, with clinical programs conducted through external trial sites.

Founding and History

QurAlis was founded to develop mechanism-driven therapies for amyotrophic lateral sclerosis. Since launch, the company has raised multiple venture financing rounds to support platform build-out and pipeline development. In 2024 and 2025, QurAlis advanced two lead programs into early clinical testing and expanded its operational footprint with a new headquarters and research facility in Cambridge.

Therapy Areas and Focus

QurAlis focuses on neurologic disease, with a primary emphasis on amyotrophic lateral sclerosis. Its development strategy targets disease mechanisms implicated in motor neuron degeneration and neuronal dysfunction. The company has also identified potential applicability of its approaches in related neurologic conditions, including epilepsy and pain.

Technology Platforms and Modalities

QurAlis develops small-molecule precision therapies directed at defined molecular drivers of neurologic disease. Its current programs address two distinct mechanisms: restoration of STMN2 expression associated with TDP-43 pathology, and modulation of neuronal excitability through selective Kv7 channel activation. Development includes both central nervous system–penetrant oral agents and intrathecal administration, depending on mechanism.

Key Personnel

Kasper Roet serves as Founder and Chief Executive Officer. The leadership team includes senior executives responsible for clinical development, medical affairs, scientific research, regulatory and drug safety, finance and operations, and business development.

Strategic Partnerships

QurAlis’ development activities are primarily internally driven and supported through venture financing. The company has not emphasized co-development partnerships for its lead programs, instead advancing assets through early clinical stages independently.

FAQ Section

QurAlis develops small-molecule therapies designed to address genetically and mechanistically defined drivers of ALS, including loss of STMN2 function and abnormal neuronal excitability.

The company’s primary focus is amyotrophic lateral sclerosis. Additional neurologic indications, including epilepsy and pain, are under evaluation in connection with specific mechanisms.

QRL-201 is a STMN2-restoring therapy in Phase I clinical development in ALS, administered intrathecally.
QRL-101 is a selective Kv7.2/7.3 channel opener in Phase I development, with programs supporting ALS and potential expansion into epilepsy and pain.

In 2025, QurAlis reported Phase I biomarker data for QRL-101 supporting proof of mechanism and opened a new global headquarters and research facility in Cambridge. The company also continued enrollment across early-stage ALS studies for both lead programs.

QurAlis has disclosed Phase I safety, tolerability, and biomarker results for QRL-101. Updates on QRL-201 have focused on study initiation and progression rather than efficacy outcomes.

Near-term milestones include completion of Phase I studies and preparation for next-stage clinical development in ALS. Regulatory interactions are aligned with early clinical progression of both programs.

QurAlis is led by executives with experience in neurodegenerative disease research, early clinical development, and biotech company building, overseeing parallel advancement of multiple first-in-class programs.

Want to Update your Company's Profile?